Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sirnaomics Ltd. ( (HK:2257) ) has issued an announcement.
Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a Phase I clinical trial of its investigational cancer drug STP707 in adults with advanced, metastatic or inoperable solid tumors that were no longer responding to standard treatments. The study showed that STP707, administered intravenously at various dose levels, demonstrated meaningful clinical activity with some patients achieving stable disease and a slowing of tumor progression, while side effects remained mostly manageable. The company has formally submitted the Clinical Study Report to the U.S. Food and Drug Administration, a milestone that positions it to begin discussions on the design and strategy for a Phase II development program, although it cautions there is no guarantee the candidate will ultimately be successfully developed or commercialized.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a biopharmaceutical company focused on developing RNA interference (RNAi)-based therapeutics, with its pipeline targeting advanced cancers and other serious diseases. Through its wholly owned subsidiary Sirnaomics, Inc., the group conducts clinical development activities primarily in the United States, aiming to bring innovative oncology treatments to patients with limited options.
Average Trading Volume: 506,821
Technical Sentiment Signal: Sell
Current Market Cap: HK$886.7M
For an in-depth examination of 2257 stock, go to TipRanks’ Overview page.